drugset / Trial / NCT01854372
Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.
NaSingle-groupOpen-labelTreatment
Summary
To estimate the I-year progression-free survival probability in patients up to 70 years of age with previously untreated diffuse large B-celllymphoma (DLBCL), or with intermediate (Burkitt-like) lymphoma, whose tumor cells show MYC rearrangement, and who are treated with alternating cycles of Rituximab-HCV AD and Rituximab-Methotrexate-Cytarabine, in concert with optimal supportive treatment including Pegfilgrastim, prophylactic antimicrobials, and close clinical follow-up.
Timeline
- Start
- 2013-06
- Primary completion
- 2013-11
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 100 mg | — |
| Subject | Cytarabine | Small molecule | 3000 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 40 mg | — |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Subject | Methotrexate | Small molecule | 12 mg | — |
| Subject | Methotrexate | Small molecule | 200 mg/m2 | — |
| Subject | Methotrexate | Small molecule | 800 mg/m2 | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Vincristine | Small molecule | 2 mg | — |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 600 mg/m2 | — |
| Background | Leucovorin | Small molecule | 15 mg | — |
| Background | Leucovorin | Small molecule | 50 mg | — |